Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyAntibody-drug conjugates as novel anti-cancer chemotherapeuticsTargeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinExpression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cellsCorrelation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyA Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaRecent advances in targeted therapy of human myelogenous leukaemia.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsXenograft models for the preclinical evaluation of new therapies in acute leukemia.Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupCD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinCellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Trends in cancer-targeted antibody-drug conjugates.Gemtuzumab ozogamicin in acute myeloid leukemia revisited.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.Gemtuzumab ozogamicin in acute myeloid leukemia.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.Antibody-Based Treatment of Acute Myeloid Leukemia.The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.Siglec-E Negatively Regulates the Activation of TLR4 by Controlling Its Endocytosis.The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
P2860
Q24678297-16DF524C-DDC9-4B04-B1CE-C9B369909623Q26800175-C31B6B7E-1E2B-4A80-8FCC-548B95EA4D7AQ28476825-04AE7697-7CA1-4991-AC02-CCCB00EBBFC2Q28484890-11391EE4-564A-48EF-83A3-F75D6C046157Q33643108-90F47EDD-28EA-4685-A669-6B6EAD293093Q34350253-317753BB-0281-4D36-A8DE-1CCBBBFF8DCBQ35909648-D1498DBE-FD72-49AD-9155-88F50D614CB6Q35950210-794F239B-4C05-48C5-8F68-08EE0EEC322CQ35980938-7312E304-2598-460D-8BED-80F894FB39DFQ36022539-71133A23-A11E-4EAD-AD03-37BFAA4A460BQ36058588-CE5A5AE0-439F-4C27-ACED-FEA8AEA52EC1Q36259762-252F8752-9E2C-4922-BC78-DEF7E7229121Q36279306-CCF0C4DA-3781-4690-9567-03ACB42DDFC0Q36318531-886E3906-BE2D-4864-8E54-C0A4B6E0150AQ36367816-05B7C336-32EC-4E45-B731-C90801D4100EQ36591404-72895FE0-E9F0-42B0-B9FE-3FC3953888B5Q36799846-6D2366E1-E9D7-454F-B59A-17ED59D06F9CQ36805474-54DEB63D-F87A-4EBC-84CA-E4B0D411C940Q36914445-70A5A032-9484-4D60-AB17-E8A1097F0741Q36932014-2B23727F-CB34-4205-A152-20267D389B0CQ37512086-E1D83056-9130-4855-B45F-C161FB9BBEA6Q37536546-52023EB4-D578-41E2-9C74-462A49C61520Q37818248-8C41A37F-3291-4BC7-9990-AC747C5C04B3Q37910260-C73E155D-E677-493D-A0A4-5FD528403757Q38109541-A0FDE2E1-AF8D-4D38-9377-4732D059FCB1Q38162127-7C624D58-BE49-4F89-9F13-B778E50D6D18Q38215269-98BCDC80-D7B1-4D7A-97CD-3ECA9B227180Q38285621-38B73DA0-001F-4557-BC2F-3A5BD315FB2EQ38537257-2F26D203-6C8C-436C-B33D-B9D16486F3C0Q38728718-355B1F74-3791-47A6-842A-BEF0B97F01C0Q38840423-892E82D9-9E01-4F83-9C9E-6D6C4DBE7211Q38979277-97C8E997-9E41-4E91-B79A-7F852D60C43BQ39484177-782BFA65-3CB3-424F-9AB7-1D6BDCF552ACQ39667028-12CB60FB-0F41-4CA7-B82D-7BD73621BE39Q39817951-D74B9B4E-CB4E-4119-8D99-604E5EDBA1AFQ40543134-DBEA3E72-F584-4EBA-94FB-C0C52BF7C1ACQ40872029-B0DC99A1-CBA8-4F89-AA54-8D54CF8FE6B9Q41264299-F46A5011-8EFB-4DF0-A247-A0DD835D6F6DQ41282870-D2B3739C-28BD-45FE-B8E0-0FCE28B2D4B8Q42315730-CB9F7200-FEB5-43E8-A1C2-C71F8F0E19B1
P2860
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Influence of CD33 expression l ...... ogamicin-induced cytotoxicity.
@en
type
label
Influence of CD33 expression l ...... ogamicin-induced cytotoxicity.
@en
prefLabel
Influence of CD33 expression l ...... ogamicin-induced cytotoxicity.
@en
P2093
P1433
P1476
Influence of CD33 expression l ...... ogamicin-induced cytotoxicity.
@en
P2093
Brian W Raden
Darren M Kamikura
Irwin D Bernstein
Jonathan A Cooper
P304
P356
10.1182/BLOOD-2004-07-2784
P407
P577
2004-09-28T00:00:00Z